Restorative <br> Heart Valve Therapy<i class=">

Heart Valve Therapy


Xeltis is a clinical-stage medical device company developing heart valves that leverage breakthrough science to transform heart valve therapy. Xeltis’ technology enables natural heart valve restoration.

RestoreX, Xeltis’ novel technology platform, is the world’s first polymer-based technology designed to enable restorative heart valve therapy.


Endogenous Tissue Restoration



ETR enables the patient’s own body to naturally restore a heart valve that is defective or no longer works. With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural and fully functional valve within it.

As ETR occurs, Xeltis’ implants are gradually absorbed by the body. ETR is enabled by the porous structure of Xeltis’ heart valves, which are made of bioabsorbable polymers, based on Nobel-prize awarded science.


Key Benefits


Xeltis’ restorative heart valves may help overcome the limitations of current artificial valves.


Xeltis' heart valves may help reduce:
• the need for repeated replacement procedures
• complications from chronic inflammation
• long-term medication with their potentially related severe side effects.


Xeltis' devices may help improve quality of life for patients with heart valve replacement.


Xeltis heart valve therapy may help reduce the overall cost of heart valve disease treatment.

Clinical Milestones

Feasibility studies of RestoreX technology with pediatric patients completed two-years follow-up.

Xeltis pediatric pulmonary valve, its anticipated first commercial product, is in clinical trials.

Xeltis aortic valve is in pre-clinical trials stage.

Nobel Prize Awarded Science

RestoreX technology is based on Nobel Prize awarded science of supramolecular chemistry by Jean-Marie Lehn – Xeltis’ Scientific Advisor.

The Future
of Heart Valve

CTO and co-Founder Martijn
Cox takes you into the lab
for a closer look at Xeltis. WATCH THE VIDEO